As of Apr 21
| -0.10 / -0.63%|
The 8 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 23.00, with a high estimate of 51.00 and a low estimate of 18.00. The median estimate represents a +45.11% increase from the last price of 15.85.
The current consensus among 9 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.